The latest trading session saw Astrazeneca (AZN) ending at $64.69, denoting a +1.32% adjustment from its last day's close. The stock outpaced the S&P 500's daily gain of 0.74%. The the stock of ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca ...

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...

Nov 5 (Reuters) - AstraZeneca (AZN.L), opens new tab shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be ...

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under ... Certain statements in this press release that are not historical facts are considered ...

The latest trading session saw Astrazeneca (AZN) ending at $64.69, denoting a +1.32% adjustment from its last day's close. The stock outpaced the S&P 500's daily gain of 0.74%. The the stock of ...

A senior AstraZeneca AZN0.91%increase; green up pointing triangle executive is under detention by Chinese authorities investigating the pharmaceutical company’s employees in the country.